Full melanotan reference list: primary sources indexed
The melanotan literature indexed below includes all citations used across this site. References are numbered to match inline citations throughout. Phase I human trials are marked CLINICAL; preclinical rodent/in vitro studies are marked PRECLINICAL; safety case reports are marked CASE REPORT; regulatory/clinical review are marked REVIEW.
-
1
Lan EL, Ugwu SO, Blanchard J, Fang X, Hruby VJ, Sharma S. Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide. J Pharm Sci. 1994;83(8):1081–1084.
-
2
Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921–930.
-
3
Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777–1784.
-
4
Hida T, Kamiya T, Kawakami A, Ogino J, Sohma H, Uhara H, Jimbow K. Elucidation of Melanogenesis Cascade for Identifying Pathophysiology and Therapeutic Approach of Pigmentary Disorders and Melanoma. Int J Mol Sci. 2020;21(17):6129.
-
5
Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389–393.
-
6
Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000;12 Suppl 4:S74–79.
-
7
Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000;56(4):641–646.
-
8
Zhang Y, Collazo R, Gao Y, Li G, Scarpace PJ. Intermittent MTII application evokes repeated anorexia and robust fat and weight loss. Peptides. 2010;31(4):639–643.
-
9
Cote I, Sakarya Y, Kirichenko N, Morgan D, Carter CS, Tumer N, Scarpace PJ. Activation of the central melanocortin system chronically reduces body mass without the necessity of long-term caloric restriction. Can J Physiol Pharmacol. 2017;95(2):206–214.
-
10
Eliason NL, Martin L, Low MJ, Sharpe AL. Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food. Neuropeptides. 2022;96:102289.
-
11
Peters B, Hadimeri H, Wahlberg R, Afghahi H. Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Rep. 2020;9(2):186–190.
-
12
Nelson ME, Bryant SM. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol (Phila). 2012;50(10):1001–1003.
-
13
Hueso-Gabriel L, Mahiques Santos L, Terraedez Mas L, Santonja Lopez N. Eruptive dysplastic nevi following melanotan use. Actas Dermosifiliogr. 2012;103(7):651–653.
-
14
Sivyer GW. Changes of melanocytic lesions induced by Melanotan injections and sun bed use in a teenage patient with FAMMM syndrome. Dermatol Pract Concept. 2012;2(3):10.
-
15
Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015;373(1):48–59.
-
16
Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172(6):1601–1612.
-
17
Ugwu SO, Blanchard J, Dorr RT, Levine N, Brooks C, Hadley ME, Aickin M, Hruby VJ. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharm Drug Dispos. 1997;18(3):259–269.
-
18
Ugwu SO, Blanchard J, Nguyen LD, Hadley ME, Dorr RT. A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats. Biopharm Drug Dispos. 1994;15(5):391–399.
-
19
Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization [PT-141/bremelanotide regulatory record]. Peptides. 2006;27(4):921–930.
-
20
Rossler AS, Pfaus JG, Kami Kia H, Bernabe J, Alexandre L, Giuliano F. The melanocortin agonist, melanotan II, enhances proceptive sexual behaviors in the female rat. Pharmacol Biochem Behav. 2006;85(3):514–521.
-
21
Ter Laak MP, Brakkee JH, Adan RA, Hamers FP, Gispen WH. The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat. Eur J Pharmacol. 2003;462(1-3):179–183.
-
22
Raposinho PD, White RB, Aubert ML. The melanocortin agonist Melanotan-II reduces the orexigenic and adipogenic effects of neuropeptide Y (NPY) but does not affect the NPY-driven suppressive effects on the gonadotropic and somatotropic axes in the male rat. J Neuroendocrinol. 2003;15(2):173–181.
-
23
Gilhooley E, Daly S, McKenna D. Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. Dermatology. 2021;237(6):998–1005.
-
24
Bonchev A. Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report. Life (Basel). 2026;16(2):265.
-
25
Alsabbagh AY, Bhujel N, Singh RP. Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? Int J Oral Maxillofac Surg. 2025;54(8):e1–e4.
-
26
Paiva L, Sabatier N, Leng G, Ludwig M. Effect of Melanotan-II on Brain Fos Immunoreactivity and Oxytocin Neuronal Activity and Secretion in Rats. J Neuroendocrinol. 2017;29(3).